Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02911571 · ClinicalTrials.gov registry record · NA
PRospective Multiple Myeloma Impact Study
A NA study of Multiple Myeloma, sponsored by SkylineDx.
- Active
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 9
- Study locations
NCT02911571 is a NA study of Multiple Myeloma that is active but no longer recruiting, run by SkylineDx. The registered enrollment target is 250 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT02911571, a NA study of Multiple Myeloma, is active but no longer recruiting, sponsored by SkylineDx.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 9
- Study locations
Study Summary
This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
Conditions Studied
Interventions
- DEVICE MMprofiler SKY92 gene signature
Study Locations (9)
New York
- New York Presbyterian Brooklyn Methodist Hospital - Brooklyn
- Columbia University Medical Center - New York
- Weill Cornell Medicine - New York
North Carolina
- Levine Cancer Institute - Charlotte
- Wake Forest Baptist Medical Center, - Winston-Salem
District of Columbia
- Lombardi Comprehensive Cancer Center - Washington D.C.
Georgia
- Winship Cancer Institute, Emory University - Atlanta
New Jersey
- Hackensack University Medical Center - Hackensack
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2018-02-27 |
| Est. Completion | 2026-09-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02911571
The ClinicalTrials.gov registry entry for NCT02911571 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (54% lower). The listed sponsor is SkylineDx, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which MMprofiler SKY92 gene signature is the first listed.
NCT02911571 reports 9 study locations spanning 6 distinct geographic areas - top geographies include New York, North Carolina, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02911571 about?
NCT02911571 is a clinical study titled "PRospective Multiple Myeloma Impact Study". This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment intention decisions in Multiple Myeloma patients.
What is the current status of trial NCT02911571?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2018-02-27. Estimated completion is 2026-09-01.
What conditions does trial NCT02911571 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT02911571?
The interventions under investigation include: MMprofiler SKY92 gene signature (DEVICE).
Who is sponsoring clinical trial NCT02911571?
This trial is sponsored by SkylineDx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02911571 being conducted?
This trial has 9 study locations across District of Columbia, Georgia, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
-
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.